Blog
RSS FeedPosted by Michael Wonder on 13 May 2019
HTA frameworks for RA therapies need improvement, researchers say
13 May 2019 - Cost-effectiveness models for the treatment of rheumatoid arthritis first emerged in the early 2000s when highly effective ...
Posted by Michael Wonder on 13 May 2019
Australia's GBMA launches hub for biosimilar education
13 May 2019 - In 2018, the Generic Biosimilar Medicines Association was awarded the Biosimilar Education Grant by the Australian government ...
Posted by Michael Wonder on 10 May 2019
Statement from Acting FDA Commissioner on policy advancements to help bring interchangeable biosimilars to market
10 May 2019 - The U.S. FDA plays an important role in helping to address the high cost of medicines ...
Posted by Michael Wonder on 28 Apr 2019
Evolus receives positive CHMP opinion for Nuceiva in the European Union
26 April 2019 - European Commission approval anticipated within 90 days. ...
Posted by Michael Wonder on 28 Apr 2019
FDA approves Samsung Bioepis' etanercept biosimilar, Eticovo
26 April 2019 - The FDA has approved Samsung Bioepis’ etanercept biosimilar, SB4, as Eticovo (etanercept-ykro). ...
Posted by Michael Wonder on 16 Apr 2019
Bach, co-authors call for regulated pricing for biologics as an alternative to biosimilars
15 April 2019 - The 2 part proposal from Peter B. Bach and 3 co-authors published Monday argues that biosimilar competition ...
Posted by Michael Wonder on 14 Apr 2019
Biopharma CEOs explain problems with biosimilars to Congress
12 April 2019 - Following their Senate Finance Committee hearing in February, all seven biopharmaceutical CEOs have now offered hundreds ...
Posted by Michael Wonder on 11 Apr 2019
Teva Canada announces the approval of Truxima, the first biosimilar to Rituxan in Canada for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and rheumatoid arthritis
10 April 2019 - Teva Canada announces that Health Canada has granted a notice of compliance for Truxima (rituximab), the ...
Posted by Michael Wonder on 09 Apr 2019
Biosimilars are a distraction
8 April 2019 - Biopharmaceutical products (also known as biologics) are among the most expensive pharmaceutical products on the market, and ...
Posted by Michael Wonder on 04 Apr 2019
Fresenius Kabi receives European Commission approval for adalimumab biosimilar Idacio
3 April 2019 - The European Commission granted Fresenius Kabi the marketing authorization for Idacio, an adalimumab biosimilar, for all indications ...
Posted by Michael Wonder on 03 Apr 2019
AbbVie's massive Humira discounts are stifling Netherlands biosimilars
2 April 2019 - Could a drug's price ever be too low? That’s what some market-watchers are asking in the ...
Posted by Michael Wonder on 03 Apr 2019
Sandoz resubmits biosimilar pegfilgrastim application to US FDA
2 April 2019 - Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim. ...
Posted by Michael Wonder on 25 Mar 2019
One Canadian payer's experience with biosimilars
25 March 2019 - Much of the discussion about biosimilar uptake revolves around challenges in the United States, but other ...
Posted by Michael Wonder on 21 Mar 2019
Promoting biosimilars up to health plans, manufacturers, doctors, Gottlieb says
21 March 2019 - As he wraps up his final weeks as commissioner of the FDA, Scott Gottlieb, MD, talked about ...
Posted by Michael Wonder on 21 Mar 2019
AbbVie is sued for using Humira patent deals to block competition in the U.S.
20 March 2019 - In a novel step, a New York union accused AbbVie and seven other drug makers of ...